The Spanish Health Economics Association (AES) organizes the pre-conference Workshop entitled “Modelling clinical trials survival data for cost-effectiveness analysis in Oncology”, which will precede its 36th Jornadas. The aim of this Workshop is to describe the methodology and use of economic evaluation of metastatic cancer treatments using of survival analysis. A large proportion of the new expensive treatments that are coming onto the market are aimed at increasing the life expectancy of patients. The results in terms of median life expectancy seen in clinical trials have, until now, been the basis for their market access. However, the length of these trials has been so far very limited and a parametric survival analysis is required in order to calculate the quality-of-life-adjusted average survival. The inclusion of cost data at patient level allows this same statistical tool to be used to construct partitioned models and calculate the incremental cost-effectiveness ratio. Real examples will be used to illustrate the different aspects. NICE is applying this methodology in a systematic manner and the speakers have been largely responsible for its development and implementation.
The speakers will be Nicholas Latimer, Senior Research Fellow in Health Economics and Decision Science at the School of Health and Related Research (ScHARR) of the University of Sheffield, and Paul Tappenden, Deputy Technical Director for the ScHARR Technology Assessment Group and a member of the NICE Decision Support Unit, renowned researchers with extensive experience in the field and international recognition.
The Workshop will be an excellent opportunity to become acquainted with the concept of parametric survival analysis using clinical trial data as well as its practical application in the economic assessment of new oncological treatments for metastatic cancers.
| 9.00-9.30 h | Registration. |
| 9.30-9.45 h | Introduction: state of economic evaluation using survival analysis in Spain. Javier Mar |
| 9.45-11.00 h | Introduction to survival analysis. Role of survival models in economic evaluation. NICE guidance. Nick Latimer |
| 11.00-11.30 h | Coffe break. |
| 11.30-12.30 h | Introduction to parametric survival analysis. |
| 12.30-13.30 h | Exercise on parametric survival analysis with STATA. Nick Latimer |
| 13.30-15.00 h | Lunch. |
| 15.00-16.00 h | Economic modelling incorporating survival analysis. Partitioned models. Paul Tappenden |
| 16.00-17.00 h | Exercise on partitioned models with Excel. Paul Tappenden |
* The Workshop will be given in English.
Javier Mar
Organización Sanitaria Integrada Alto Deba. Mondragón.
Nicholas Latimer. Economist and Senior Research Fellow in Health Economics and Decision Science at the School of Health and Related Research of the University of Sheffield. His research interests focus on economic evaluation methodology, with a particular emphasis on the incorporation of survival analysis within economic models and more specifically on methods for adjusting survival estimates in the presence of treatment switching in clinical trials. He has authored two NICE Decision Support Unit technical support documents, on survival analysis (TSD14, 2011) and on treatment switching (TSD16, 2014). His publications on parametric adjustments in survival analysis are international points of reference in the field.
Paul Tappenden. Deputy Technical Director for the School of Health and Related Research Technology Assessment Group at the University of Sheffield and a member of the NICE Decision Support Unit and of NICE Technology Appraisal Committee C. His main research interests are health economic modelling, economic analyses of therapies for multiple sclerosis, economic analyses of cancer therapies and whole disease modelling. He has been involved in studies to model cost-effectiveness for NICE, including modelling the cost-effectiveness of a treatment for multiple sclerosis, of influenza prophylaxis and of technologies for the prevention, detection, treatment and follow-up of colorectal cancer.
